Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

171.79USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$171.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
613,341
52-wk High
$256.78
52-wk Low
$142.83

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -11.66 -- --
ROI: -3.08 15.07 14.61
ROE: -5.61 16.60 16.34

U.S. court rejects Allergan bid to shield patents through tribe deal

A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.

20 Jul 2018

UPDATE 2-U.S. court rejects Allergan bid to shield patents through tribe deal

July 20 A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.

20 Jul 2018

U.S. court rejects Allergan bid to shield patents through tribe deal

July 20 A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.

20 Jul 2018

Allergan, Molecular Partners eye drug meets main goal in two studies

Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.

19 Jul 2018

UPDATE 1-Allergan, Molecular Partners eye drug meets main goal in two studies

July 19 Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.

19 Jul 2018

Allergan, Molecular Partners eye drug meets main goal in two studies

July 19 Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies.

19 Jul 2018

BRIEF-Molecular Partners And Allergan Announce Two Positive Phase 3 Clinical Trials

* Allergan And Molecular Partners Announce Two Positive Phase 3 Clinical Trials For Abicipar Pegol 8 And 12-Week Regimens For The Treatment In Patients With Neovascular Age-Related Macular Degeneration Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Jul 2018

BRIEF-Allergan And Molecular Partners Announce Two Positive Phase 3 Clinical Trials

* ALLERGAN AND MOLECULAR PARTNERS ANNOUNCE TWO POSITIVE PHASE 3 CLINICAL TRIALS FOR ABICIPAR PEGOL 8 AND 12-WEEK REGIMENS FOR THE TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

19 Jul 2018

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

14 Jun 2018

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

14 Jun 2018

Earnings vs. Estimates